Sugi Predict

Sugi Predict / Compounds / SCHEMBL8223754

SCHEMBL8223754

SCHEMBL8223754

CC(C)(C)OC(=O)CCCC=O

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HDAC6 Q9UBN7 3/20 0.40
▸ HDAC8 Q9BY41 2/20 0.40
▸ HDAC1 Q13547 2/20 0.40
▸ HDAC2 Q92769 2/20 0.40
▸ HDAC3 O15379 1/20 0.40
▸ EPHX2 P34913 1/20 0.37
▸ HIF1A Q16665 1/20 0.36
▸ TSHR P16473 3/20 0.36
▸ MAPT P10636 1/20 0.35
▸ CTSK P43235 2/20 0.34
▸ ALDH1A1 P00352 1/20 0.33
▸ NR1I2 O75469 1/20 0.33
▸ PGR P06401 1/20 0.33
▸ ADORA3 P0DMS8 1/20 0.33
▸ PTGS2 P35354 1/20 0.33
▸ PDE4D Q08499 1/20 0.33
▸ LMNA P02545 1/20 0.33
▸ STING1 Q86WV6 1/20 0.32
▸ TDP1 Q9NUW8 1/20 0.32
▸ MAOA P21397 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17309612 0.94 ALDH1A1 (0.40) HDAC6HDAC8HDAC1HDAC2HDAC3
SCHEMBL29066249 0.92 ALDH1A1 (0.43) HDAC6HDAC8HDAC1HDAC2HDAC3
SCHEMBL31240161 0.92 ALDH1A1 (0.43) HDAC6HDAC8HDAC1HDAC2HDAC3
SCHEMBL30552478 0.92 ALDH1A1 (0.43) HDAC6HDAC8HDAC1HDAC2HDAC3
SCHEMBL19292207 0.92 ALDH1A1 (0.43) HDAC6HDAC8HDAC1HDAC2HDAC3
SCHEMBL31110583 0.92 ALDH1A1 (0.43) HDAC6HDAC8HDAC1HDAC2HDAC3
SCHEMBL30864371 0.92 ALDH1A1 (0.43) HDAC6HDAC8HDAC1HDAC2HDAC3
SCHEMBL31211601 0.92 ALDH1A1 (0.43) HDAC6HDAC8HDAC1HDAC2HDAC3
SCHEMBL9431001 0.92 ALDH1A1 (0.43) HDAC6HDAC8HDAC1HDAC2HDAC3
SCHEMBL28240505 0.92 ALDH1A1 (0.43) HDAC6HDAC8HDAC1HDAC2HDAC3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 138 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4688790-A1 MACROCYCLIC RAS INHIBITORS Revolution Medicines, Inc. (US) 2026-02-11 — — EP disclosed
US-20260035388-A1 HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS INCYTE CORP (US) 2026-02-05 — — US disclosed
US-20260028353-A1 MACROCYCLIC RAS INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION, AS ADMINISTRATIVE AGENT 2026-01-29 — — US disclosed
EP-4565585-A1 COMPOUNDS FOR MODULATING RET PROTEIN Bristol-Myers Squibb Company (US) 2025-06-11 — — EP disclosed
US-12310955-B2 Cyclic amide compounds for rabies treatment and method thereof IRIMAJIRI THERAPEUTICS INC. (JP) 2025-05-27 — — US disclosed
CN-120004860-A Sulfur-containing isoindoline derivative, preparation method thereof and application thereof in medicine 江苏恒瑞医药股份有限公司 2025-05-16 — — CN disclosed
CN-120004859-A Sulfur-containing isoindoline derivative, preparation method thereof and application thereof in medicine 江苏恒瑞医药股份有限公司 2025-05-16 — — CN disclosed
CN-116253719-B Estrogen and androgen receptor dual degradation agent and application thereof 苏州国匡医药科技有限公司 2025-04-01 — — CN disclosed
CN-119731179-A IKZF2 degradation agent and application thereof 密歇根大学董事会 2025-03-28 — — CN disclosed
WO-2025056073-A1 INDAZOLONE COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION, AND USE 中国科学院上海药物研究所 2025-03-20 — — WO disclosed
CN-102112451-B Diazepan and piperazine derivatives modulators of chemokine receptors HOFFMANN LA ROCHE 2014-01-22 — — CN disclosed
CN-102822165-A Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same CELGENE CORP 2012-12-12 — — CN disclosed
CN-102686577-A Compounds as tyrosine kinase modulators ALLERGAN INC 2012-09-19 — — CN disclosed
US-7820858-B2 Concise β2-amino acid synthesis via organocatalytic aminomethylation WISCONSIN ALUMNI RESEARCH FOUNDATION (US) 2010-10-26 — — US disclosed
US-7820858-B2 Concise β2-amino acid synthesis via organocatalytic aminomethylation WISCONSIN ALUMNI RESEARCH FOUNDATION (US) 2010-10-26 — — US disclosed
CN-101687874-A Pyrrolotriazine kinase inhibitors BRISTOL MYERS SQUIBB CO 2010-03-31 — — CN disclosed
US-20080058548-A1 CONCISE BETA2-AMINO ACID SYNTHESIS VIA ORGANOCATALYTIC AMINOMETHYLATION WISCONSIN ALUMNI RESEARCH FOUNDATION (WARF) (US) 2008-03-06 — — US disclosed
US-20080058548-A1 CONCISE BETA2-AMINO ACID SYNTHESIS VIA ORGANOCATALYTIC AMINOMETHYLATION WISCONSIN ALUMNI RESEARCH FOUNDATION (WARF) (US) 2008-03-06 — — US disclosed
WO-2007143014-A2 METHODS FOR PREPARING GLUTAMIC ACID DERIVATIVES AND INTERMEDIATES THEREOF WYETH (US) 2007-12-13 — — WO disclosed
CN-1159289-C C-terminal modified oxamyl dipeptides as inhibitors of the ICE/ced-3 family of cystenine proteases ������˹ҩƷ��˾ 2004-07-28 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260028353-A1 MACROCYCLIC RAS INHIBITORS KRAS, NRAS, HRAS HDAC6 369/4885HDAC8 468/4885HDAC1 382/4885
US-20080058548-A1 CONCISE BETA2-AMINO ACID SYNTHESIS VIA ORGANOCATALYTIC AMINOMETHYLATION BCAT2, AADAT, BCAT1 HDAC6 2101/4885HDAC8 2475/4885HDAC1 2463/4885
US-20260035388-A1 HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS IL2, IL4, NFATC1 HDAC6 351/4885HDAC8 460/4885HDAC1 97/4885
US-12310955-B2 Cyclic amide compounds for rabies treatment and method thereof F12, RXFP3, AVPR1B HDAC6 194/4885HDAC8 416/4885HDAC1 103/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.